A new study published in The Lancet Infectious Diseases confirms that the Qdenga dengue vaccine is clinically effective during the massive 2024 outbreak in São Paulo, Brazil.
Results show that after just one dose, Qdenga reduced symptomatic dengue cases by about 50%, and after two doses, protection rose to 62%, while hospitalizations dropped by 68%. Immunity began developing within 14 days of the first shot.
Researchers highlight this as the first real-world evidence—beyond clinical trials—demonstrating that Qdenga can prevent both mild and severe dengue, marking a key milestone for public health policy in outbreak-prone regions and for travelers visiting at-risk areas.
Related posts:
Thailand is preparing to implement its Climate Change Act (Global Warming Act) in 2026, m...
A study from Ohio State University has found that people who live within about 48 kilomet...
In the northern part of Tanzania, near the Kenyan border, there is a lake called Lake Nat...
Researchers from the University of Cambridge have discovered that certain species of bact...
